| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
MSB Stock Overview
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland.
Mesoblast Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.86 |
| 52 Week High | AU$2.08 |
| 52 Week Low | AU$0.61 |
| Beta | 2.57 |
| 1 Month Change | 4.22% |
| 3 Month Change | -13.07% |
| 1 Year Change | -57.39% |
| 3 Year Change | -41.55% |
| 5 Year Change | -49.86% |
| Change since IPO | 8.13% |
Recent News & Updates
Does Mesoblast (ASX:MSB) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Shareholder Returns
| MSB | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -2.8% | 0.1% | 0.7% |
| 1Y | -57.4% | -1.3% | -8.0% |
Return vs Industry: MSB underperformed the Australian Biotechs industry which returned -1.3% over the past year.
Return vs Market: MSB underperformed the Australian Market which returned -8% over the past year.
Price Volatility
| MSB volatility | |
|---|---|
| MSB Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 10.5% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 4.6% |
Stable Share Price: MSB is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: MSB's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 83 | Silviu Itescu | https://www.mesoblast.com |
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Mesoblast Limited Fundamentals Summary
| MSB fundamental statistics | |
|---|---|
| Market Cap | US$423.08m |
| Earnings (TTM) | -US$91.95m |
| Revenue (TTM) | US$9.98m |
39.4x
P/S Ratio-4.3x
P/E RatioIs MSB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MSB income statement (TTM) | |
|---|---|
| Revenue | US$9.98m |
| Cost of Revenue | US$79.74m |
| Gross Profit | -US$69.76m |
| Other Expenses | US$22.19m |
| Earnings | -US$91.95m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.14 |
| Gross Margin | -698.78% |
| Net Profit Margin | -921.09% |
| Debt/Equity Ratio | 18.2% |
How did MSB perform over the long term?
See historical performance and comparison